New research in testicular cancer, ASCO-GU 2017

At the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium, researchers presented the results of a single-arm trial investigating the efficacy of a single cycle of bleomycin, etoposide, and cisplatin (BEP) as adjuvant chemotherapy for high-risk, stage 1, non-seminomatous or combined germ cell tumours of the testis (NSGCTT).1 The 236 subjects received one cycle of BEP, with etoposide dosed at 165mg/m2 Day 1–3 and cisplatin 50 mg/m2 Days 1 and 2. They were followed for five years post-orchiectomy. The primary efficacy endpoint was malignant recurrence at two years, defined as active undifferentiated disease ± rising markers, multiple site relapse. Teratoma differentiated recurrence was a secondary endpoint